Jefferies Reiterates Buy Rating on AdaptHealth (AHCO) as Investor Day Points to 8% Organic Growth

Jefferies analyst Brian Tanquilut reiterated a Buy rating and $35.00 price target on AdaptHealth (NASDAQ: AHCO) after the company's investor day which points to 8% organic growth.

The analyst commented, "We came away from AHCO's first investor day with a positive view as mgmt articulated how they can drive organic revenue CAGR of ~8% over the next few years (incl CPAP recover in '23), which translates to a revenue goal of $4B in 2025 (from $2.9B this yr). Mgmt also pointed to an EBITDA goal of $1B in '25, which implies expectations for margin expansion. This earnings power should also translate to improved FCF, with mgmt guiding to ~$300MM of FCF in '25."

For an analyst ratings summary and ratings history on AdaptHealth click here. For more ratings news on AdaptHealth click here.

Shares of AdaptHealth closed at $22.12 yesterday.

You May Also Be Interested In

• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Cisco rating cut at HSBC as analyst sees a lack of catalysts
• Target (TGT) PT Raised to $146 at Piper Sandler